NCT00194649View on ClinicalTrials.gov

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Contraception
Interventions
DRUG

Miglustat (Zavesca)

100 mg Miglustat BID (twice daily) for six weeks

Trial Locations (1)

98195

University of Washington, Seattle

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Washington

OTHER

NCT00194649 - Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) | Biotech Hunter | Biotech Hunter